JHVEPhotoBausch Health Companies Overview In May 2024, Bausch Health Companies (NYSE:BHC) posted first-quarter results. The stock plunged from over $10 ahead of the report and continued its descent afterward. Despite its opportunities for growth in its Xifaxan product and the value of its Solta Medical unit, markets stayed away from the stock. Last month, thanks to a strong stock market, BHC stock looked like it bottomed at $6.00. The steady uptrend in Bausch Health stock ended abruptly on July 24, 2024 ...